Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Given Consensus Recommendation of “Hold” by Analysts

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) has received a consensus rating of “Hold” from the nine analysts that are covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, three have given a hold recommendation and five have issued a buy recommendation on the company. The average twelve-month price objective among brokerages that have updated their coverage on the stock in the last year is $9.00.

INO has been the subject of several recent research reports. Wall Street Zen lowered Inovio Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, August 16th. Zacks Research downgraded shares of Inovio Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Wednesday, September 3rd. UBS Group reissued an “overweight” rating on shares of Inovio Pharmaceuticals in a research report on Friday, November 14th. Citigroup reaffirmed a “market outperform” rating on shares of Inovio Pharmaceuticals in a research report on Tuesday, November 4th. Finally, Piper Sandler reissued an “overweight” rating and set a $6.00 target price (up previously from $5.00) on shares of Inovio Pharmaceuticals in a research report on Friday, November 14th.

Inovio Pharmaceuticals Stock Performance

NASDAQ:INO opened at $2.07 on Friday. The firm has a 50-day simple moving average of $2.22 and a 200-day simple moving average of $2.05. Inovio Pharmaceuticals has a one year low of $1.30 and a one year high of $4.44. The firm has a market cap of $138.13 million, a P/E ratio of -0.80 and a beta of 1.54.

Inovio Pharmaceuticals (NASDAQ:INO) last issued its quarterly earnings data on Monday, November 10th. The biopharmaceutical company reported ($0.44) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.51) by $0.07. On average, research analysts predict that Inovio Pharmaceuticals will post -4.23 EPS for the current fiscal year.

Institutional Trading of Inovio Pharmaceuticals

A number of institutional investors have recently made changes to their positions in the business. Nuveen LLC acquired a new position in shares of Inovio Pharmaceuticals in the 1st quarter valued at about $168,000. Charles Schwab Investment Management Inc. raised its position in Inovio Pharmaceuticals by 38.6% during the first quarter. Charles Schwab Investment Management Inc. now owns 98,495 shares of the biopharmaceutical company’s stock valued at $161,000 after acquiring an additional 27,429 shares in the last quarter. XTX Topco Ltd lifted its holdings in Inovio Pharmaceuticals by 26.7% in the first quarter. XTX Topco Ltd now owns 66,169 shares of the biopharmaceutical company’s stock valued at $108,000 after acquiring an additional 13,939 shares during the period. Nomura Holdings Inc. purchased a new stake in Inovio Pharmaceuticals in the 1st quarter worth approximately $28,000. Finally, Y Intercept Hong Kong Ltd purchased a new stake in Inovio Pharmaceuticals in the 2nd quarter worth approximately $86,000. Institutional investors and hedge funds own 26.79% of the company’s stock.

Inovio Pharmaceuticals Company Profile

Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.